« Back
Home /
Mitoxantrone

Mitoxantrone

Item no.	HY-13502-100mg
Manufacturer	MedChem Express
CASRN	65271-80-9
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 50 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.58
Citations	[1]Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7.\|[2]Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.\|[3]Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8.\|[4]Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62.\|[5]Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. Acta Pharmacol Sin. 2022 Aug 31.\|Acta Pharmacol Sin. 2024 Aug 15.\|Adv Mater. 2024 Apr 21:e2313097.\|bioRxiv. 2024 September 07.\|BMC Cancer. 2025 Jan 7;25(1):24.\|Cancers. 2020 Aug 4;12(8):2169.\|Cell Rep Med. 2024 Feb 20;5(2):101388.\|Drug Metab Dispos. 2025 Feb 3.\|EMBO Mol Med. 2024 Oct 11.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Int J Biol Macromol. 2025 Jan 9:139582.\|Int J Biol Sci. 2022 Mar 21;18(6):2568-2582.\|J Am Chem Soc. 2022 Jun 15;144(23):10407-10416.\|J Control Release. 2024 Nov 12:376:1271-1287.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|J Pharm Pharmacol. 2022 Jan 5;74(1):41-56.\|J Pharm Pharmacol. 23 November 2021.\|Light Sci Appl. 2024 Oct 31;13(1):304.\|Mol Cell. 2024 Jun 18:S1097-2765(24)00447-7.\|Nat Cell Biol. 2024 May 7.\|Patent. US20240307414A1.\|Pharm Dev Technol. 2021 Apr 30;1-9.\|Pharmacol Res. 2024 May 9:204:107208.\|Research Square Print. November 28th, 2022.\|Talanta. 2024 Mar 23, 125987.\|University of California, Irvine. 2024.\|bioRxiv. 2023 Jan 13.\|BMC Cancer. 2021 Oct 13;21(1):1101.\|Cell Oncol. 2020 Dec;43(6):1099-1116.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Drug Deliv. 2022 Dec;29(1):2561-2578.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Med Oncol. 2020 Nov 19;37(12):116.\|Nat Commun. 2020 Apr 14;11(1):1792.
Smiles	O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Mitozantrone,NSC 301739
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Endogenous Metabolite; Orthopoxvirus; PKC; Topoisomerase
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light)
Molecular Weight	444.48
Product Description	Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity[1][2][3][4]. Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively[5].
Manufacturer - Research Area	Cancer; Infection
Solubility	DMSO : 35 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; TGF-beta/Smad
Clinical information	Launched
Isoform	PKC; Topo II

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.